INT77290

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.33
First Reported 1995
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 15
Total Number 18
Disease Relevance 10.17
Pain Relevance 4.97

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
aortic arch 1
cardiogenic 1
asa (Mus musculus)
Pain Link Frequency Relevance Heat
aspirin 387 100.00 Very High Very High Very High
Enkephalin 30 100.00 Very High Very High Very High
cva 11 99.92 Very High Very High Very High
Potency 21 98.80 Very High Very High Very High
Angina 9 95.74 Very High Very High Very High
Inflammation 166 83.76 Quite High
adenocard 2 81.08 Quite High
cINOD 185 80.88 Quite High
imagery 3 71.40 Quite High
anesthesia 32 68.92 Quite High
Disease Link Frequency Relevance Heat
Cv General 3 Under Development 12 99.92 Very High Very High Very High
Persian Gulf Syndrome 5 99.84 Very High Very High Very High
Myocardial Infarction 18 99.54 Very High Very High Very High
Cancer 358 99.52 Very High Very High Very High
Death 68 99.24 Very High Very High Very High
Cv Unclassified Under Development 2 99.00 Very High Very High Very High
Apoptosis 102 98.56 Very High Very High Very High
Cv General 2 Under Development 2 98.24 Very High Very High Very High
Pulmonary Embolism 1 97.48 Very High Very High Very High
Bacillus Anthracis Infection 3 97.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The variables studied were: age, gender, hematocrit and hemoglobin levels, scopolamine use, diagnostic or therapeutic exam, American Society of Anesthesiologists Scores (ASA), duration time of exam, sedative used midazolam in the average of 0.07 mg/kg and analgesic drug meperidine in the average of 0.7 mg/kg that was titrated according patients reaction.
Gene_expression (levels) of ASA
1) Confidence 0.33 Published 2004 Journal Arq Gastroenterol Section Body Doc Link 15678200 Disease Relevance 0 Pain Relevance 0
High dose ASA resulted in a decreased expression of thrombomodulin at the bifurcation compared with control mice (p?
Gene_expression (resulted) of ASA associated with aspirin
2) Confidence 0.30 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2943480 Disease Relevance 0.13 Pain Relevance 0.26
High dose ASA reduced the number of initial lesions in the unirradiated aortic arch, but once again the effect was not maintained in the irradiated mice.
Gene_expression (reduced) of ASA in aortic arch associated with aspirin
3) Confidence 0.30 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2943480 Disease Relevance 0.74 Pain Relevance 0.46
Neither NCX 4016 nor high dose ASA had an effect on the expression levels of eNOS (Figure 4E).


Gene_expression (expression) of ASA associated with aspirin
4) Confidence 0.30 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2943480 Disease Relevance 0.18 Pain Relevance 0.32
These results suggest that the production of ASA in GWS patients is linked to the presence of squalene in certain lots of anthrax vaccine.
Gene_expression (production) of ASA associated with persian gulf syndrome and bacillus anthracis infection
5) Confidence 0.29 Published 2002 Journal Exp. Mol. Pathol. Section Abstract Doc Link 12127050 Disease Relevance 0.44 Pain Relevance 0
Next, we tested the effect of NCX 4016 and high dose ASA on the expression levels of these molecules.
Gene_expression (expression) of ASA associated with aspirin
6) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2943480 Disease Relevance 0.12 Pain Relevance 0.22
of NO-ASA is its extraordinarily enhanced potency.
Gene_expression (is) of NO-ASA associated with potency
7) Confidence 0.22 Published 2008 Journal PPAR Research Section Body Doc Link PMC2408682 Disease Relevance 0.79 Pain Relevance 0.05
azoxymethane, NO-indomethacin and meta NO-ASA significantly suppressed
Gene_expression (azoxymethane) of NO-ASA
8) Confidence 0.22 Published 2008 Journal PPAR Research Section Body Doc Link PMC2408682 Disease Relevance 1.37 Pain Relevance 0.21
established that NO-ASA, which is now FDA approved for clinical trials,
Gene_expression (established) of NO-ASA
9) Confidence 0.22 Published 2008 Journal PPAR Research Section Body Doc Link PMC2408682 Disease Relevance 0.48 Pain Relevance 0.46
azoxymethane, NO-indomethacin and meta NO-ASA significantly suppressed
Gene_expression (suppressed) of NO-ASA
10) Confidence 0.22 Published 2008 Journal PPAR Research Section Body Doc Link PMC2408682 Disease Relevance 1.36 Pain Relevance 0.21
reported that NO-ASA induces two types of cell death, classical apoptosis as
Gene_expression (induces) of NO-ASA associated with apoptosis and death
11) Confidence 0.22 Published 2008 Journal PPAR Research Section Body Doc Link PMC2408682 Disease Relevance 0.93 Pain Relevance 0
was sparse, and treatment with NO-ASA had no
Neg (no) Gene_expression (had) of NO-ASA
12) Confidence 0.22 Published 2008 Journal PPAR Research Section Body Doc Link PMC2408682 Disease Relevance 0.56 Pain Relevance 0.03
As depicted, samples from RML prion-inoculated animals were active in the ASA whereas samples from BSA-inoculated Tg9949 mice were not (Fig. 1E, top).
Gene_expression (active) of ASA
13) Confidence 0.20 Published 2010 Journal PLoS Pathogens Section Body Doc Link PMC2809756 Disease Relevance 0.55 Pain Relevance 0.13
The magnitude of the in vitro and in vivo resistance of 3 synthetic enkephalin analogs, [D-Ala2,Met5]-enkephalin (DAME), [D-Ala2,Met5]-enkephalinamide (DAME-NH2) and [D-Ala2,D-Met5]enkephalin (DADME), to 3 enkephalin-hydrolyzing enzymes, amastatin-sensitive aminopeptidase (AsA), phosphoramidon-sensitive endopeptidase-24.11 (PsE) and captopril-sensitive dipeptidyl carboxypeptidase I (CsD), was estimated by comparing the potency of enkephalins in the absence of the peptidase inhibitor (PI) with that in the presence of the PI.
Gene_expression (resistance) of AsA associated with enkephalin and potency
14) Confidence 0.08 Published 1995 Journal Regul. Pept. Section Abstract Doc Link 12506418 Disease Relevance 0 Pain Relevance 1.47
However, it is not practical in patients undergoing revascularization procedures because most are classified as ASA III.
Gene_expression (classified) of ASA
15) Confidence 0.07 Published 2008 Journal J. Vasc. Surg. Section Abstract Doc Link 18280093 Disease Relevance 0.09 Pain Relevance 0
Complications of ASA, although rare in high volume centers, occur in the early post-procedural period and include LAD dissection, coronary artery spasm, cardiac tamponade, cardiogenic shock, pulmonary embolism and stroke.
Gene_expression (dissection) of ASA in cardiogenic associated with pulmonary embolism, stroke, cv general 2 under development, cv unclassified under development and cva
16) Confidence 0.07 Published 2008 Journal Current Cardiology Reviews Section Body Doc Link PMC2780820 Disease Relevance 0.95 Pain Relevance 0.18
The collagen/epinephrine closure times were significantly longer in UA patients (median, 233 s) than in untreated controls (median, 125 s; P < 0.0001), as expected, but there was no difference in MI patients (median, 149.24 s; P > 0.05), suggesting that the MI patients were not all responding to ASA.
Neg (not) Gene_expression (responding) of ASA associated with aspirin, angina and myocardial infarction
17) Confidence 0.03 Published 2005 Journal Blood Coagul. Fibrinolysis Section Abstract Doc Link 16269928 Disease Relevance 1.48 Pain Relevance 0.97
CONCLUSIONS: (i) Gastric adaptation to aspirin injury involves enhanced cell proliferation which appears to be mediated by increased expression of SP and TGF alpha, and (ii) rapid upregulation of COX-2 expression following single and repeated ASA insults may represent a compensatory response to suppression of prostaglandin generation by this NSAID.


Gene_expression (expression) of ASA
18) Confidence 0.01 Published 1998 Journal Aliment. Pharmacol. Ther. Section Body Doc Link 9726391 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox